` TTOO (T2 Biosystems Inc) vs S&P 500 Comparison - Alpha Spread

TTOO
vs
S&P 500

Over the past 12 months, TTOO has underperformed S&P 500, delivering a return of -98% compared to the S&P 500's 9% growth.

Stocks Performance
TTOO vs S&P 500

Loading
TTOO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TTOO vs S&P 500

Loading
TTOO
S&P 500
Difference
www.alphaspread.com

Performance By Year
TTOO vs S&P 500

Loading
TTOO
S&P 500
Add Stock

Competitors Performance
T2 Biosystems Inc vs Peers

S&P 500
TTOO
ABBV
AMGN
GILD
VRTX
Add Stock

T2 Biosystems Inc
Glance View

Market Cap
3.6m USD
Industry
Biotechnology

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 182 full-time employees. The company went IPO on 2014-08-07. The firm is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The firm is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common blood stream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis.

TTOO Intrinsic Value
Not Available
Back to Top